RT Journal Article
SR Electronic
T1 Radiation and a Metalloporphyrin Radioprotectant in a Mouse Prostate Tumor Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3101
OP 3109
VO 27
IS 5A
A1 DAILA S. GRIDLEY
A1 ADEOLA Y. MAKINDE
A1 XIAN LUO
A1 ASMA RIZVI
A1 JAMES D. CRAPO
A1 MARK W. DEWHIRST
A1 BENJAMIN J. MOELLER
A1 ROBERT D. PEARLSTEIN
A1 JAMES M. SLATER
YR 2007
UL http://ar.iiarjournals.org/content/27/5A/3101.abstract
AB Background: Antioxidants have the potential to protect normal tissues against radiation-induced damage, but must not protect tumor cells during radiotherapy. The major objectives were to determine whether a metalloporphyrin antioxidant affects prostate tumor response to radiation and identify possible mechanisms of interaction. Materials and Methods: C57BL/6 mice with RM-9 tumor were treated with manganese (III) meso-tetrakis(1,3-diethylimidazolium-2-yl)porphyrin (MnTDE-2-ImP) and 10 gray (Gy) radiation. Tumor volume was quantified and a subset/group was evaluated for hypoxia-inducible factor-1α (HIF-1α), bone marrow-derived cell populations and cytokines. Results: The addition of MnTDE-2-ImP transiently increased tumor response compared to radiation alone. The group receiving drug plus radiation had reduced intratumoral HIF-1α and decreased capacity to secrete TNF-α, whereas production of IL-4 was increased. There were no toxicities associated with combination treatment. Conclusion: The results demonstrate that MnTDE-2-ImP did not protect the RM-9 prostate tumor against radiation; instead, radiation effectiveness was modestly increased. Possible mechanisms include reduction of radiation-induced HIF-1α and an altered cytokine profile. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved